Lyra Therapeutics reports disappointing results for LYR-210 in Phase 3 chronic rhinosinusitis trial
Lyra Therapeutics, Inc. (Nasdaq: LYRA), dedicated to advancing treatments for chronic rhinosinusitis (CRS), announced that its Phase 3 ENLIGHTEN 1 trial evaluating LYR-210 did not ... Read More
Lyra Therapeutics raises $30m for chronic rhinosinusitis drug candidates
Lyra Therapeutics has raised $30 million in a Series C financing round to advance its lead product candidates for the treatment of chronic rhinosinusitis (CRS). ... Read More